Choroidal melanoma metastasized to the ovary:case report and review of the literature

Background: Malignant melanoma metastases to the female genital tract in only 2.5% of cases. Melanoma is characterized by clinical variability and unpredictable biological behavior with long remissions and relapses that develop rapidly. Case and review: A 57-year-old woman was admitted for hypogastric pain and weight loss. She had presented enucleation of the right eye six years before for malignant choroid melanoma. Gynaecological examination revealed enlarged ovaries. Bilateral salpingo-oophorectomy, hysterectomy, and omentectomy were performed. Final pathology diagnosed a choroidal metastatic melanoma (CMM). The patient died seven months later. Only seven cases of CMM have been reported in the literature. Patients affected by CMM ranged in age from 38 to 83 years (median 51.2 years), the time to relapse ranged from 3-25 years (median 51.2 years), the size of the cysts ranged from 4-17 cm (median 9.7 cm) and the survival period ranged from 2-14 months (median 8.1 months). Conclusion: Malignant melanoma is misdiagnosed because of lack of discriminatory symptoms, increased tumor markers, characteristic imaging findings and the capacity to mimic other tumors. Today CMM still represents a challenge for gynecologic oncologists.

Choroidal melanoma; Ovary; Metastasis; Diagnosis; Staging; Treatment.

[1] Landis S.H., Murray T., Bolden S., Wingo P.A.: “Cancer statis-tics”. CA Cancer J. Clin., 1998, 48, 6.

[2] Irvin W.P., Legallo R.L., Stoler M.H., Rice L.W., Taylor P.T., Andersen W.A.: “Vulvar melanoma: a retrospective analysis and literature review”. Gynecol. Oncol., 2001, 83, 457.

[3] Lotem M., Anteby S., Peretz T., Ingber A., Avinoach I., Prus D.: “Mucosal melanoma of the female genital tract is a multifocal disorder”. Gynecol. Oncol., 2003, 88, 45.

[4] Ariel I.M.: “Malignant melanoma of the female genital system: a report of 48 patients and review of the literature”. J. Surg. Oncol., 1981, 16, 371.

[5] Dawson H.G.W.: “Melanotic sarcoma of choroid and ovary”. BMJ, 1922, 2, 757.

[6] Ben David M., Feldberg D., Dicker D., Kessler H., Goldman J.A.: “Ovarian melanoma. An interesting case”. Int. J. Gynaecol. Obstet., 1984, 22, 77.

[7] Thiery M., Willighagen R.: “Melanoma of the female genital tract”. Gynaecologia, 1966, 161, 466.

[8] Santeusanio G., Ventura L., Mauriello A., Carosi M., Spagnoli L. G., Maturo P. et al.: “Isolated ovarian metastasis from a spindle cell malignant melanoma of the choroids 14 years after enucleation:prognostic implication of the keratin immunophenotype”. Appl. Immunohistochem. Mol. Morphol., 2000, 8, 329.

[9] Rey-Caballero V.E., Lopez-Gonzalez B., Garcia-Benitez J.L., Boix-Fos A., Diaz-Lagama A.M.: “Solitary ovarian metastasis from ocular melanoma”. Am. J. Obstet. Gynecol., 2004, 191, 368.

[10] Coutts M.A., Borthwick N.J., Hungerford J.L., Cree I.A.: “Post-menopausal bleeding: a rare presentation of metastatic uveal melanoma”. Pathol. Oncol. Res., 2006, 12, 184.

[11] Bloch-Marcotte C., Ambrosetti D., Novellas S., Caramella T., Dahman M., Thyss A., Chevallier P.: “Ovarian metastasis from choroidal melanoma”. Clin. Imag., 2008, 32, 318.

[12] Piura B., Yanai-Inbar I., Rabinovich A., Zalmanov S., Goldstein J.: “Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy”. Eur. J. Obstet. Gynecol. Reprod. Biol., 1999, 83, 57.

[13] Walfisch S., Lapid O., Yanai-Inbar I., Piura B.: “Sigmoid colon carcinoma metastatic to the myometrium”. Eur. J. Obstet. Gynecol. Reprod. Biol., 1999, 86, 65.

[14] Foss A.J., Cree I.A., Dolin P.J., Hungerford J.L.: “Modelling uveal melanoma”. Br. J. Ophthalmol., 1999, 83, 588.

[15] Pandey M., Prakash O., Mathews A., Nayak N., Ramachandran K.: “Choroidal melanoma metastasizing to maxillofacial bones”. World J. Surg. Oncol., 2007, 5, 30.

[16] Demirici H., Shields C.L., Chao A.N., Shields J.A.: “Uveal metastasis from breast cancer in 264 patients”. Am. J. Ophthalmol., 2003, 136, 264.

[17] Shields J.A., Augsburger J.J., Donoso L.A., Bernardino V.B., Portenar M.: “Hepatic metastasis and orbital recurrence of uveal melanoma after 42 years”. Am. J. Ophthalmol., 1985, 100, 666.

[18] Nakano J., Shimizu T., Hirota T., Muto M.: “An usual female melanoma patient with late metastases to both skin and ovaries”.

J. Dermatol., 1998, 25, 126.

[19] Gupta D., Deavers M.T., Silva E.G., Malpica A.: “Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases”. Am. J. Surg. Pathol., 2004, 28, 771.

[20] Ayhan A., Guvenal T., Salman M.C., Ozyuncu O., Sakinci M., Basaran M.: “The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries”. Gynecol. Oncol., 2005, 98, 231.

[21] Fuller P.N.: “Malignant melanoma of the ovary and exposure to clomiphene citrate: A case report and review of the literature”. Am.

J. Obstet. Gynecol., 1999, 180, 1499.

[22] Oliver R., Dasgupta C., Coker A., Al-Okati D., Weekes A.R.: “Ovarian malignant melanoma: unusual presentation of a solitary metastasis”. Gynecol. Oncol., 2005, 99, 412.

[23] Brown D.L., Zou K.H., Tempany C.M., Mary C., Frates M.C., Silverman S.G. et al.: “Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study”. Radiology, 2001, 219, 213.

[24] Moselhi M., Spencer J., Lane G.: “Malignant melanoma metastatic to the ovary: presentation and radiological characteristics”. Gynecol. Oncol., 1998, 69, 165.

[25] Holder W.D.,White R.L., Zuger J.H., Easton E.J., Green F.L.: “Effectiveness of positron emission tomography for the detection of melanoma metastases”. Ann. Surg., 1998, 227, 764.

[26] McCluggage W.G., Bissonnette J.P., Young R.H.: “Primary malignant melanoma of the ovary: a report of 9 definite or probable cases with emphasis on their morphologic diversity and mimicry of other primary and secondary ovarian neoplasm”. Int. J. Gynecol. Pathol., 2006, 25, 321.

[27] Pietzner K., Noske A., Cho C.H., Kiecker F., Sehouli J.: “Amelanotic metastasis of melanoma mimicking ovarian cancer: a case report and review of the literature”. Anticancer Res., 2008, 28, 563.

[28] McCluggage W.G., Maxwell P.: “Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours”. Histopathology, 2001, 38, 403.

[29] Stewart C.J., Nandini C.L., Richmond J.A.: “Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian neoplasms”. Appl. Immunohistochem. Mol. Morphol., 2003, 11, 244.

[30] Nogales F.F.: “Germ cell tumours of the ovary”. In: Fox H., Wells

M. (eds.). Haines and Taylor Obstetrical and Gynecological Pathology. New York, Churchill Livingstone, 1995, 847.

[31] Deavers M.T., Malpica A., Ordonez N.G., Silva E.G.: “Ovarian steroid cell tumors: an immunohistochemical study including a comparison of calretinin with inhibin”. Int. J. Gynecol. Pathol., 2003, 22, 162.

[32] Peterson W.F.: “Malignant degeneration of benign cystic teratomas of the ovary: a collective review of literature”. Obstet. Gynecol. Surv., 1957, 12, 793.

[33] McNeilage L.J., Morgan J., Constable J., Jobling T.W.: “Metastatic malignant melanoma arising in a mature ovarian cystic teratoma: a case report and literature review”. Int. J. Gynecol. Cancer, 2005, 15, 1148.

[34] Cronje H.S., Woodruff J.D.: “Primary ovarian malignant melanoma arising in cystic teratoma”. Gynecol. Oncol., 1981, 12, 379.

[35] Legha S.S., Ring S., Eton O. et al.: “Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma”. J. Clin. Oncol., 1998, 16, 1752.